Company
Johnson & Johnson
Johnson & Johnson, American healthcare company developing surgical robots (Auris Health/Monarch platform for bronchoscopy) and robotic orthopedics (Ottava).
- Founded
- 1886
- HQ
- New Brunswick, NJ
- Status
- public (NYSE: JNJ)
- Models
- 2
Verified profile
3
Sources on record
2
Tracked changes
Updated 14 days ago
Last verified change
Key facts
Product
Ottava unified-architecture four-arm soft-tissue surgical robot (announced 2020).
Status
Pre-market: FDA De Novo submitted Jan 7 2026; NOT cleared; zero installed base.
Stock listing
NYSE: JNJ
Developing division
MedTech/Ethicon
Company type
Global healthcare company
Deploy Watch
Track Johnson & Johnson on Deploy.
We notify you when a verified state change lands on the record, not when the company issues a claim.
Data & sources
- Press releases1
- News coverage1
- Web sources1
3 sources backing this record.View all →
Models (2)
View all models →Current platform
Johnson & Johnson Ottava
Next-generation surgical robot in development by J&J/Ethicon. 6-arm configuration, general surgery focus.
Current platform
Ottava
Johnson & Johnson (NYSE: JNJ; founded 1886, New Brunswick, New Jersey), through its MedTech and Ethicon division, is developing Ottava, a soft-tissue general-surgery robotic platform with a unified architecture of four arms integrated into the operating table, announced in 2020 and repeatedly delayed. The critical audit finding is that as of mid-2026 Ottava is pre-market: J&J submitted it to the FDA via a De Novo classification application on January 7, 2026 for multiple upper-abdomen general-surgery procedures, and the company's own language states it is under development and not authorized to be marketed or sold in any market. Investigational first cases were completed in early 2025 at Memorial Hermann in the Texas Medical Center, with a second investigational study for inguinal hernia approved in late 2025. The registry records Ottava at research maturity, because under the verified-vs-claimed framework no regulatory clearance means research-tier regardless of corporate scale or demonstrations, and Ottava has no clearance and zero installed base, only investigational-trial cases. An aggregator claim that Ottava was targeted for commercial launch in late 2025 or early 2026 is contradicted by the primary J&J source and is not registered. For context, J&J's separate Monarch robotic bronchoscopy, acquired through Auris in 2019, and its Velys robotic knee-replacement system are already FDA-cleared commercial products, but Ottava is the soft-tissue surgical-robot entity and remains pre-market.
Safety record
No incidents on record for Johnson & Johnson.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Recent coverage
Johnson & Johnson in third-party press
Peer companies
- Intuitive Surgical2 models
- Stryker2 models
- Vantis2 models
- Asensus Surgical1 model
- Auris Health1 model
- Brain Navi1 model
Financial state
- Reporting basis
- aggregator_estimate
- Lifecycle stage
- mature
- Counterparty risk class
- low
Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.
Acquisitions (1)
- acquired Auris Healthfull acquisition
Sources (3)
- https://www.jnj.com/media-center/press-releases/johnson-johnson-submits-ottava-robotic-surgical-system-to-the-u-s-food-and-drug-administration
- https://www.medtechdive.com/news/jnj-layoffs-auris-california-robotic/644544/
- https://www.fiercebiotech.com/medtech/jj-to-take-over-verb-surgical-its-robotics-venture-verily
Common questions
- What is Johnson & Johnson?
- Johnson & Johnson, American healthcare company developing surgical robots (Auris Health/Monarch platform for bronchoscopy) and robotic orthopedics (Ottava).
- Where is Johnson & Johnson based?
- Johnson & Johnson is based in New Brunswick, NJ.
- When was Johnson & Johnson founded?
- Johnson & Johnson was founded in 1886.
- What does Johnson & Johnson make?
- Johnson & Johnson has 2 robot models on the DEPLOY registry: Johnson & Johnson Ottava, Ottava (Johnson & Johnson builds both physical robots and the AI that runs them).
- Where does Johnson & Johnson operate robots?
- Johnson & Johnson is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.
- Is Johnson & Johnson safe?
- Johnson & Johnson has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 3 sources (1 primary) · last reviewed 2026-07-03
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-07-03
Sources by quality tier
- 1
- primary-company-ir
- Company IR disclosure
- 1
- secondary-trade-publication
- Trade publication
- 1
- unclassified
- Unclassified source
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Johnson & Johnson.Peer companies
- Intuitive Surgical2 models
- Stryker2 models
- Vantis2 models
- Asensus Surgical1 model
- Auris Health1 model
- Brain Navi1 model
In the press
Recent coverage mentioning Johnson & Johnson from third-party publications. Automatically surfaced; not part of the verified registry record.
DePuy Synthes Appoints Andrew Burton as Global Head of Robotics - hrtoday.in
<a…
J&J’s DePuy Synthes has a new global head of robotics - MassDevice
<a…
Medical robotics and AI advice from a J&J DePuy Synthes leader
“Don’t lead with AI,” he says. “AI for its own sake doesn’t mean anything. You have to start with talking to surgeons about real problems and things that would meaningfully change…
How J&J’s DePuy Synthes developed Velys software for faster hip replacements
Ahead of Johnson & Johnson MedTech‘s launch of its new Velys Hip Navigation with AI Assistance software, we interviewed DePuy Synthes President of Global Digital, Robotics Surgery…
Johnson & Johnson (JNJ): A Cheap Robotics Stock Redefining Coronary Artery Disease Treatment - Yahoo Finance
<a…
How Investors May Respond To Johnson & Johnson (JNJ) Advancing Immunology, Cardiology And Surgical Robotics Platforms - Yahoo Finance
<a…
Johnson & Johnson completes clinical study for OTTAVA robotic surgical system - The Robot Report
<a…
J&J’s Ottava surgical robot meets primary endpoints in gastric bypass study - Fierce Biotech
<a…
J&J’s Ottava robot meets goals in gastric bypass study - MedTech Dive
<a…
J&J's Space-Saving Ottava Robot Passes Clinical Test - Medical Device and Diagnostic industry
<a…
Johnson & Johnson’s Ottava Robot Meets Endpoints in Pivotal Bariatric Surgery Trial - Medical Product Outsourcing
<a…
Johnson & Johnson says Ottava surgical robot met endpoints in pivotal bariatric surgery study - MassDevice
<a…
Machine-readable surfaces
- Markdown mirror: /companies/johnson-and-johnson.md
- RSS feed: /companies/johnson-and-johnson/feed.xml
- JSON-LD: embedded in this page’s head
- REST API: /v1/companies/766676f2-56d0-4910-81dc-03703d6c9c40
- Revision history: /companies/johnson-and-johnson/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Peer companies
- Intuitive Surgical2 models
- Stryker2 models
- Vantis2 models
- Asensus Surgical1 model
- Auris Health1 model
- Brain Navi1 model
DEPLOY Intelligence Score
33.2/ 100
6-month trend
Analysis
Clean safety record across 2 verified deployments. Limited public funding data for capital position assessment.
Signal flags
Dimension breakdown
Safety Record
Market Presence
Deployment Scale
Funding Health
IP Activity
Hiring Signal
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
Last computed: Jul 3, 2026
Intelligence layer